Team:Slovenia/Notebook

From 2012.igem.org

(Difference between revisions)
Line 717: Line 717:
 +
<br/>
 +
<p><a href="https://2012.igem.org/wiki/index.php?title=Team:Slovenia/Notebook#naslov">Back to top</a></p>
 +
<h2><a name="inductionsystems"> Induction systems </a></h2>
 +
 +
<h3>Induction systems</h3>
 +
 +
<p>To control our switch we needed a way to affect it from the outside. For this purpose we chose several inducible transcription systems where the controlled gene is expressed when a small molecule inducer (such as tetracycline) is present and is not expressed when the inducer is absent. We chose specific systems which do not cross react and whose inducers are orally bioavailable and safe for human use (Clackson, 2000). The systems we chose are based on tetracycline, pristinamycin, erythromycin and rapamycin analogs, as inducers. We then adapted these systems by cloning TAL regulators under their control to make them compatible with our genetic circuits. </p>
 +
 +
<h3>Tetracycline, erythromycin and pristinamycin systems</h3>
 +
 +
<p>The tetracycline, erythromycin and pristinamycin system all function in a similar manner. They are composed of a DNA binding protein (such as TetR) fused to a KRAB domain which reversibly binds a specific DNA sequence (TRE for example) and silences transcription from nearby promoters. The addition of an inducer causes the DNA binding domain to dissociate from the DNA and allows transcription to start. (Deuschle et al., 1995) (Kramer et al., 2004) </p>
 +
 +
 +
<img src="X"></img>
 +
<p><b> Figure 1: Induced expression of TAL
 +
</b>.</p>
 +
 +
<p>TABLE</p>
 +
 +
 +
<h3>Rapamycin system</h3>
 +
 +
<p>In the rapamycin system the gene of interest is under the control of a minimal promoter. The gene's transcription rate is regulated by two proteins that consist of a drug binding domain and either a DNA binding domain or an activation domain. When rapamycin is added both drug binding domains bind to it, consequently joining the activation domain with the DNA binding domain, resulting in a functional transcription factor, which activates the gene of interest. Instead of rapamycin a rapamycin analogue (rapalogue), which is a 1000-fold less imunosupressive than rapamycin, but activates the inducible system like rapamycin, is usualy used as the inducer. (Pollock et al., 2002) </p>
 +
 +
 +
<p>TABLE</p>
 +
 +
 +
</p>
 +
<h2 style="color:grey;">References</h2>
 +
<p style="color:grey;">
 +
Clackson, T. (2000) Regulated gene expression systems. <i> Gene ther.</i> <b>7</b>, 120–125.<br/><br/>
 +
Deuschle, U., Meyer, W.K. and Thiesen, R. (1995) Tetracycline-reversible silencing of eukaryotic promoters. <i>Mol. Cell. Biol. </i> <b>15</b>, 1907–1914.<br/><br/>
 +
Kramer, B.P., Fischer, C. and Fussenegger, M. (2004) BioLogic gates enable logical transcription control in mammalian cells. <i> Biotech. Bioeng.</i> <b>87</b>, 478–484.<br/><br/>
 +
Pollock, R. and Clackson, T. (2002) Dimerizer-regulated gene expression. <i> Curr. Opin. Biotech. i> <b>13</b>, 459–467.<br/><br/>
 +
</p>
Line 723: Line 759:
-
<br/>
 
-
<p><a href="https://2012.igem.org/wiki/index.php?title=Team:Slovenia/Notebook#naslov">Back to top</a></p>
 
-
<h2><a name="inductionsystems"> Induction systems </a></h2>
 
The induction systems are described <a href="https://2012.igem.org/Team:Slovenia/Parts">here</a>.  
The induction systems are described <a href="https://2012.igem.org/Team:Slovenia/Parts">here</a>.  
<p> </p>
<p> </p>

Revision as of 20:53, 26 September 2012